The natural history of malignancies under conditions of BRAF inhibitor stimulation

Expert Opin Investig Drugs. 2011 Jan;20(1):135-6. doi: 10.1517/13543784.2011.542325. Epub 2010 Nov 30.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Carcinoma, Squamous Cell / epidemiology
  • Carcinoma, Squamous Cell / etiology*
  • Carcinoma, Squamous Cell / pathology
  • Humans
  • Indoles / adverse effects
  • Indoles / pharmacology*
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Melanoma / pathology
  • Mutation
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics
  • Risk Factors
  • Skin Neoplasms / epidemiology
  • Skin Neoplasms / etiology
  • Skin Neoplasms / pathology
  • Sulfonamides / adverse effects
  • Sulfonamides / pharmacology*
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Indoles
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf